Gastrinomas are neuroendocrine neoplasms (NENs), that occur primarily in the duodenum
and pancreas, which ectopically secrete gastrin, resulting in the Zollinger-Ellison syndrome …

The dramatic success of pharmacological acid suppression in healing peptic ulcers and
managing patients with gastroesophageal reflux disease (GERD) has been reflected in the …

Background: The neuroendocrine marker, chromogranin A (CgA) increases during medium-
or long-term proton-pump inhibitor (PPI) treatment. Aims: To analyze the effect of ultra-short …

Recently, two epidemiological studies showed that long-term treatment with proton pump
inhibitors (PPIs) increased the risk of gastric cancer. It is well known that hypergastrinemia …

Gastrin is an important hormone of the digestive system, which assists gastric acid secretion.
It may be pathologically elevated in conditions such as Zollinger-Ellison syndrome, or due to …

The use of proton pump inhibitors (PPIs) over the last 30 years has rapidly increased both in
the United States and worldwide. PPIs are not only very widely used both for approved …

Background Rebound gastric hyperacidity (RGH) secondary to hypergastrinemia has been
suggested to contribute to the rapid recurrence of equine squamous gastric disease (ESGD) …

Despite general awareness of Zollinger-Ellison syndrome (ZES) by most physicians and
more than 3000 articles written about it since 1955, the diagnosis of ZES is still delayed for a …

Background and aim. Fasting serum gastrin-17 (FsG17) is considered as a noninvasive
biomarker reflecting the structure and functional status of gastric mucosa, but its clinical …

Whether the long-term treatment of patients with proton pump inhibitors (PPIs) with different
diseases [GERD, Zollinger–Ellison syndrome (ZES), etc.] can result in vitamin B12 (VB12) …